Last reviewed · How we verify

NBI-1117570

Neurocrine Biosciences · Phase 2 active Small molecule Quality 0/100

NBI-1117570 is a novel compound under development by Neurocrine Biosciences for the treatment of schizophrenia. Currently in Phase 2 trials, it aims to address unmet needs in this psychiatric disorder. No FDA label is available yet, and safety data are limited.

At a glance

Generic nameNBI-1117570
SponsorNeurocrine Biosciences
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: